Table 3.

Correlation of PFS with responsiveness to lapatinib

Blinded analysis by HVLab*
HER-2 statusnHR (95% CI)P
Positive2550.47 (0.32-0.67)<0.001
Negative860.54 (0.30-0.99)0.046
Blinded reanalysis by ALab*
HER-2 status
n
HR (95% CI)
P
Positive2710.46 (0.33-0.65)<0.001
Negative470.94 (0.39-2.28)0.888
HR by FISH ratios in blinded reanalysis
FISH ratios
n
HR (95% CI)
P
<2.03901.09 (0.86-1.37)0.486
2.0-5.5820.48 (0.28-0.83)0.009
5.5-7.6890.35 (0.18-0.69)0.002
7.6-10.1870.58 (0.33-1.05)0.072
≥10.1880.42 (0.24-0.74)0.003
  • * Analysis of cases with results from the EGF100151 clinical trial.

  • Analysis of all cases in the ALab for patients in either clinical trial.